Program
Anti-IL-11 Monoclonal Antibody 9MW3811
Also written as “9MW3811 Injection” and “9MW3811 injection”.
Its studies are mostly in Cicatrix · Pulmonary Fibrosis · Idiopathic Pulmonary Fibrosis, led by Mabwell (Shanghai) Bioscience.
Drug pageAnti-IL-11 Monoclonal Antibody 9MW3811: every studyAll 4 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Mabwell (Shanghai) Bioscience | 43 open or running | phase 2since Apr 12, 2026 | Feb 2, 2023 | Dec 2026phase 2 · NCT07576608 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 2, 2023First study: phase 1 study in Pulmonary FibrosisFirst studyNCT05740475 · 32 enrolled · Australia
- Jun 12, 20232 phase 1 studiesNCT05912049, NCT05911984
- Apr 12, 2026Phase 2 study in CicatrixPhase 2 reachedNCT07576608 · 30 planned · China
Ahead
- Dec 2026Primary completion: phase 2 study in CicatrixNCT07576608
TargetBeta
“A humanized monoclonal antibody directed against interleukin-11 (IL-11), ”NCIt, by rule
Other programs on IL11
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| BI 765423 | Boehringer Ingelheim | phase 2 | 3 |
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07576608Cicatrix · China | 2 | Recruiting | Dec 2026 | 30 |
| NCT05912049Idiopathic Pulmonary Fibrosis · China | 1 | Recruiting | Dec 2023 | 24 |
| NCT05911984Advanced Malignant Solid Tumor · China | 1 | Not yet recruiting | Mar 2024 | 27 |
| NCT05740475Pulmonary Fibrosis · Australia | 1 | Completed | Sep 14, 2023 | 32 |
How it is read
Names in the registry
- “9MW3811 Injection”, 3 entries
- “9MW3811 injection”, 1 entry
Conditions, from the studies’ own filings
- Cicatrix, 1 study
- Pulmonary Fibrosis, 1 study
- Idiopathic Pulmonary Fibrosis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.